How many employees does AnaptysBio, Inc. have?

AnaptysBio, Inc. reported 104 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 3, 2026. That is down 23.5% from a year earlier.

What is AnaptysBio, Inc.'s revenue per employee?

AnaptysBio, Inc. brought in $235M of revenue in fiscal Dec 2025, which is $2.26M per employee. That ranks 7 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

AnaptysBio, Inc. employees and revenue per employee

ANAB · Biotechnology · $1.36B market cap

AnaptysBio, Inc. had 104 employees at the end of fiscal Dec 2025, down 23.5% from a year earlier. Revenue for the year was $235M, up 157.0% from a year earlier, or $2.26M per employee. Revenue held up or grew while headcount stayed flat or fell.

Employees

104

-23.5% YoY

Revenue

$235M

+157.0% YoY

Revenue / employee

$2.26M

Peer median $459K

Rank in industry

7 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

ANAB employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	104	$235M	$2.26M	-23.5%	+157.0%
Dec 2024	136	$91.3M	$671K	+16.2%	+432.0%
Dec 2023	117	$17.2M	$147K	+21.9%	+66.8%
Dec 2022	96	$10.3M	$107K	-5.9%	-83.7%
Dec 2021	102	$63.2M	$619K	+8.5%	-15.8%
Dec 2020	94	$75.0M	$798K	+5.6%	+837.5%
Dec 2019	89	$8.0M	$90K	+14.1%	+60.0%
Dec 2018	78	$5.0M	$64K	+30.0%	-50.0%
Dec 2017	60	$10.0M	$167K	+22.4%	-40.1%
Dec 2016	49	$16.7M	$340K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

AnaptysBio, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
LGND Ligand Pharmaceuticals Incorporated	47	$268M	$5.70M	Leaner
ANAB AnaptysBio, Inc.	104	$235M	$2.26M	Leaner
IDYA IDEAYA Biosciences, Inc.	145	$219M	$1.51M	Efficient growth
PBYI Puma Biotechnology, Inc.	179	$228M	$1.28M	Hiring into decline
ARVN Arvinas, Inc.	246	$263M	$1.07M	Contracting
VCEL Vericel Corporation	398	$276M	$694K	Efficient growth
ADPT Adaptive Biotechnologies Corporation	624	$277M	$444K	Efficient growth
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
IOVA Iovance Biotherapeutics, Inc.	975	$264M	$270K	Efficient growth

Every Healthcare company

Questions about AnaptysBio, Inc.

How many employees does AnaptysBio, Inc. have?: AnaptysBio, Inc. reported 104 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 3, 2026. That is down 23.5% from a year earlier.
What is AnaptysBio, Inc.'s revenue per employee?: AnaptysBio, Inc. brought in $235M of revenue in fiscal Dec 2025, which is $2.26M per employee. That ranks 7 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare ANAB with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in AnaptysBio, Inc.'s annual reports (Form 10-K), latest filed March 3, 2026. This is data, not a recommendation to buy or sell ANAB.